Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cinnamon Oil→

Cinnamon Oil Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
8015-91-6
Molecular formula
Not available
Molecular weight
Not available
Drug class
Botanical essential oilCinnamomum species volatile oil
Mechanism of action
Contains volatile constituents such as cinnamaldehyde and eugenol, with local antimicrobial and sensory effects in laboratory studies. The chemical profile depends on plant species, plant part and extraction method; no single therapeutic mechanism can be assigned to all cinnamon oils.
Indications / reported uses
  • Traditional flavouring and fragrance ingredient and, in selected products, topical or oral herbal preparation. No general FDA/EMA-approved medicinal indication can be assigned to cinnamon oil without a specific standardised product and label.

Sources: EMA herbal medicinal products overview · PubMed — Cinnamon essential oil pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Cinnamon Oil Environmental Risk Assessment (ERA) (the Cinnamon Oil ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.